drugset / Trial / NCT03730948
DC Vaccine in Colorectal Cancer
Phase 1
Terminated
4 enrolled
University of Pennsylvania
National Cancer Institute (NCI) · collabParker Institute for Cancer Immunotherapy · collab
NaSingle-groupOpen-labelTreatment
Summary
This is a pilot study to assess the safety and tolerability, as well as the immune response rate, of mDC3 vaccine in patients with colorectal cancer.
Timeline
- Start
- 2019-03-12
- Primary completion
- 2022-02-22
- Completion
- 2022-12-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | DC vaccine | Vaccine | — | — |